InDex Pharmaceuticals Holding AB (1NP1) Stock Price & Analysis

5 Followers

1NP1 Stock Chart & Stats

€1.06€0.01(0.47%)

At close: Nov 06 5:30 PM GMT+1

Day’s Range: EUR 1.05 - EUR 1.06
52-Week Range: EUR 1.05 - EUR 3.16
Previous Close: EUR 1.06
Volume: N/A
Average Volume (3M): 2,241
Market Cap: EUR 106.02M
Enterprise Value: EUR 1.15B
Total Cash (Recent Filing): EUR 265.10M
Total Debt (Recent Filing): EUR 1.60M
Price to Earnings (P/E): ―
Beta: 0.14
Next Earnings: Jan 20, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage

Exceptionally low leverage reduces fixed financial obligations and gives InDex greater flexibility while its pipeline remains in development. A largely unlevered balance sheet can provide more capacity to absorb operating losses, pursue clinical work, or structure future funding without substantial debt-service pressure.

Focused Immunology Pipeline

A focused therapeutic strategy gives InDex a clearly defined development identity rather than a broad and diffuse portfolio. Concentration on inflammatory and autoimmune diseases, anchored by cobitolimod, can support specialized clinical expertise and more coherent partnering efforts over the medium term.

Substantial Capital Base

The reported asset and equity base provides a meaningful financial foundation relative to the company’s development-stage operations. Although it is not currently producing positive returns, this capital base may support continued regulatory and clinical activities and offers some resilience as management pursues partnering opportunities.

Bears Say

Persistent Cash Burn

Sustained negative operating and free cash flow means the business is consuming cash rather than funding development internally. Continued outflows increase dependence on future financing, partnering proceeds, or other capital sources, potentially limiting strategic flexibility if clinical and regulatory spending remains elevated.

Severe Unprofitability

Very large ongoing net losses show that InDex has not yet converted its development activities into sustainable earnings. This weak profitability reduces internal funding capacity, makes operating performance highly dependent on future asset progress, and increases the financial consequences of delays or unsuccessful programs.

Volatile Revenue And Partner Dependence

Revenue has not followed a stable growth path, falling sharply from the 2023 level and becoming negative on a TTM basis. Because the model relies on licensing, milestones, and eventual royalties, future revenue visibility remains tied to partner agreements and successful clinical and regulatory execution.

1NP1 FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was €1.05 and its highest was €3.16 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is €106.02M.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Oct 15, 2026. The company reported -€0.29 earnings per share for the quarter.

Is InDex Pharmaceuticals Holding AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -€0.29 in its last earnings report. Following the earnings report the stock price went down -8.099%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in DE:1NP1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description